dr. weber on the fda approval of adjuvant dabrafenib/trametinib in braf-mutant melanoma
Published 6 years ago • 210 plays • Length 1:11Download video MP4
Download video MP3
Similar videos
-
0:18
copy of dr. weber on the fda approval of adjuvant dabrafenib/trametinib in braf-mutant melanoma
-
0:30
dr. postow on fda approval of adjuvant dabrafenib plus trametinib in braf-mutant melanoma
-
1:08
fda approval of adjuvant dabrafenib/trametinib in braf melanoma
-
1:46
dr. weber on dabrafenib/trametinib approval for melanoma
-
1:08
dr. weber on dabrafenib/trametinib versus vemurafenib/cobimetinib in melanoma
-
1:27
dr. weber on side effects of dabrafenib/trametinib in melanoma
-
0:59
dr. weber on the fda approval for fixed-dose of nivolumab
-
1:31
dr. daud on dabrafenib/trametinib vs immunotherapy in melanoma
-
1:52
dr. long on dabrafenib/trametinib in braf v600e-mutant melanoma
-
0:57
dr. weber on fda approval of pembrolizumab for stage iii melanoma
-
2:19
dr. robert on 5-year analysis of dabrafenib/trametinib in braf v600-mutant melanoma
-
1:26
dr. nathan on long-term outcomes with dabrafenib/trametinib in braf v600-mutant melanoma
-
1:15
dr. weber on nivolumab in the adjuvant setting for melanoma
-
1:04
dr. wilson on long-term data with dabrafenib plus trametinib in melanoma
-
1:22
dr. weber on adjuvant pembrolizumab in melanoma
-
4:12
adjuvant therapy in melanoma: combi-ad trial
-
2:16
dr. rodabe n. amaria on dabrafenib plus trametinib in melanoma
-
0:53
dabrafenib plus trametinib demonstrates benefit in braf-mutant melanoma
-
0:59
the success of the dabrafenib and trametinib combination in braf-mutated melanoma